Key facts, as of
As of September 29, 2026, Regeneron Pharmaceuticals (REGN) trades at $750.51, up 33.8% over the past year. Its 52-week range runs from $541.00 to $859.34; the price is 12.7% below that high. It sits 2.0% above its 200-day average of $736.11, the usual sign of a long-term uptrend. Its 30-day volatility is 30.2% annualized, which we rate high risk. It has a trailing P/E of 18.6 and a dividend yield of 0.50%.
Cite: Portfolio Terminal, "Regeneron Pharmaceuticals (REGN) stock analysis", 2026-09-29. https://portfolio-terminal.com/analyse/regn
Where it trades today
trading 66% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- REGN trades at 18.6x earnings versus 22.0x for the sector, which means the rerating case depends on proving the discount is too harsh.
- Recent realized volatility is running around 30.2%, above the sector norm of 22.0%, so position sizing matters more than usual.
- REGN remains in a bearish short-term trend and sits 12.7% below its high, which raises the bar for any thesis that depends on fast multiple expansion.
Portfolio Use Case
- REGN is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A recovery in price alone would not be enough to improve the view; the thesis needs confirmation from improving business or valuation signals.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for REGN come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for REGN. Last refresh: Sep 29, 2026, 10:33 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Regeneron Pharmaceuticals does
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent…
What analysts expect
REGN carries a buy consensus from 26 analysts, with an average price target of $850.88 versus $750.51 today (+13.4%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
REGN generated $15.53B in trailing revenue (16.7% year over year), with a 27.9% net margin, and $3.07B of free cash flow, supported by $5.29B of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $14.34B | $12.24B | $3.70B | $4.50B | $43.07 | $3.77B |
| 2024 | $14.20B | $12.23B | $3.99B | $4.41B | $40.90 | $3.54B |
| 2023 | $13.12B | $11.30B | $4.05B | $3.95B | $37.05 | $3.67B |
| 2022 | $12.17B | $10.61B | $4.74B | $4.34B | $40.51 | $3.40B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
REGN beside the healthcare names it is usually measured against.
What the chart is saying
Slipped under its 50-day average inside a longer uptrend.
weakening- Price is 3.8% below its 50-day average and 2.0% above its 200-day.
- The 50-day crossed above the 200-day on 2026-09-03 (a “golden cross”).
- RSI at 37 is neither stretched nor washed out.
- The nearest ceiling is $774.66 (+3.2%), the nearest floor $729.14 (-2.8%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is REGN a good buy right now?
Regeneron Pharmaceuticals trades at 18.6x earnings. This is near market average. Current risk level is High based on 30.2% volatility.
Does REGN pay dividends?
Yes, Regeneron Pharmaceuticals offers a dividend yield of 0.50%. That is roughly $3.75 per share a year.
How volatile is REGN?
With 30-day annualized volatility of 30.2% and beta of 0.19, REGN is classified as High risk. The stock tends to be more stable than the market average.
What is the analyst price target for REGN?
The average analyst price target for Regeneron Pharmaceuticals (REGN) is $850.88 based on 26 analyst estimates, about 13.4% above the current price of $750.51. The published range runs from $730.00 to $1030.00.
How much revenue does REGN generate?
Regeneron Pharmaceuticals reported $15.53B in trailing twelve-month revenue. Revenue growth is running at 16.7% year over year. Net margin sits at 27.9%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare REGN with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.